Skip to main content
Eurofins-Cerep logo

Eurofins-Cerep — Investor Relations & Filings

Ticker · ALECR ISIN · FR0013256518 LEI · 9695004C9D3ZX7FTZY16 PA Professional, scientific and technical activities
Open in API
Filings indexed 53 across all filing types
Latest filing 2009-01-07 Regulatory Filings
Country FR France
Listing PA ALECR

About Eurofins-Cerep

https://www.eurofins.fr

Eurofins-Cerep is a Contract Research Organization (CRO) specializing in pre-clinical drug discovery services. The company provides solutions for in vitro drug profiling and screening in pharmacology, supporting pharmaceutical, biopharmaceutical, and biotechnology companies in the early stages of new drug development. Its services focus on delivering critical data regarding the biological activity and potential liabilities of chemical compounds, which aids clients in the identification and optimization of promising drug candidates before they proceed to clinical trials.

Recent filings

Filing Released Lang Actions
Cerep annonce la signature d’un accord de licence avec Théa pour le développement de son antagoniste LFA-1 dans l’ophtalmologie
Regulatory Filings Classification · 85% confidence The document is a press release dated January 7, 2009, announcing a licensing agreement between Cerep and Théa for the development of an LFA-1 antagonist for ophthalmology. This announcement details a specific corporate transaction involving licensing, future milestone payments, and royalties. This type of announcement, which concerns strategic business development and financing terms (though not direct capital raising), fits best under the 'Capital/Financing Update' (CAP) category if it involves significant financial terms, or potentially 'Regulatory Filings' (RNS) if it's a general market disclosure. Given the focus on a licensing deal with defined financial components (upfront payment, milestones, royalties), it relates closely to the company's financial structure and future revenue streams. However, none of the specific codes perfectly capture a 'Licensing Agreement Announcement'. Since it is a formal announcement of a significant business development with financial implications, and it is not a standard report (10-K, IR, ER), nor a management change (MANG) or dividend (DIV), the most appropriate classification among the provided options that covers significant corporate actions with financial impact, or general market disclosures, is often RNS (Regulatory Filings) as a fallback, or potentially CAP if the focus is heavily on the financial structure change. Given the context of a press release announcing a deal structure, it is a significant corporate event disclosure. Since there is no specific 'M&A/Partnership' code, and it is not a proxy, earnings, or board change, I will classify it as a general Regulatory Filing (RNS) as it is a material non-standard announcement, or consider if it aligns with CAP. CAP is for fundraising/financing/capital structure changes. A licensing deal is a form of strategic financing/monetization. Given the options, RNS is the safest general disclosure category, but since it involves future payments and development rights, it is a material business transaction. I will lean towards RNS as the most general fit for a press release announcing a specific, material business deal that doesn't fit the other specific financial/reporting codes.
2009-01-07 French
Communiqué sur les recommandations AFEP/MEDEF relatives à la rémunération des dirigeants et mandataires sociaux
Remuneration Information Classification · 95% confidence The document is a press release dated December 22, 2008, titled "Communiqué sur les recommandations AFEP/MEDEF relatives à la rémunération des dirigeants et mandataires sociaux" (Communiqué on the AFEP/MEDEF recommendations regarding the remuneration of executives and corporate officers). It explicitly mentions that the board took note of the AFEP/MEDEF recommendations concerning executive compensation and that the report required by Article L 225.37 of the Commercial Code will be prepared in accordance with these recommendations. This content directly relates to the compensation and remuneration structure of top executives and directors. Based on the provided definitions, the category 'Remuneration Information (Code: DEF 14A)' is the most appropriate fit, as DEF 14A filings in the US context cover proxy statements which detail executive compensation, aligning with the subject matter here.
2008-12-22 French
Cerep signs a license agreement with sanofi-aventis and receives the first milestone payment
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "press release" dated December 10, 2008, announcing a specific corporate event: the signature of a license agreement with sanofi-aventis and the receipt of a milestone payment. This type of announcement, detailing a significant business development (licensing, partnership success, financing event), is best categorized as a general corporate announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ), it falls under the general regulatory/corporate announcement category. Given the options, 'Regulatory Filings' (RNS) serves as the best fit for miscellaneous, non-standardized corporate news releases that don't match the more specific categories like CAP (Capital/Financing Update) or TAR (M&A Activity). While it involves financing (milestone payment), the core event is the agreement signature, making RNS the most appropriate general catch-all for this type of press release.
2008-12-10 English
Cerep annonce la conclusion d’un accord de licence avec sanofi-aventis et reçoit un premier paiement d’étape
Capital/Financing Update Classification · 85% confidence The document is a press release dated December 10, 2008, announcing a licensing agreement between Cerep and sanofi-aventis regarding a drug candidate. This announcement details a specific corporate transaction (licensing, milestone payment, royalties) related to drug development. This type of announcement, which is not a standard periodic financial report (like 10-K or IR), nor a management change (MANG), nor a dividend notice (DIV), nor a general regulatory filing (RNS), best fits the category for updates on financing activities or capital structure changes, as licensing deals often involve upfront payments and future financial obligations. However, given the specific options, it is a corporate action announcement. Since it is not explicitly about fundraising (CAP), share issues (SHA/POS), M&A (TAR), or insider trading (DIRS), it is a general corporate announcement. In the context of the provided definitions, 'Capital/Financing Update (CAP)' is the closest fit for a significant financial transaction like a licensing deal that includes milestone payments and royalties, as it directly impacts the company's financial structure and future revenue streams. It is too specific for the general 'RNS' fallback.
2008-12-10 French
Information financière trimestrielle - 3ème trimestre 2008
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly financial update for Cerep for the third quarter of 2008. It provides consolidated revenue figures, cash position, and business highlights for the period. While it is a summary, it contains substantive financial data and analysis for an interim period, fitting the definition of an Interim/Quarterly Report (IR). It is not merely an announcement of a report (RPA) as it provides the actual financial results directly in the text. 9M 2008
2008-11-12 French
Third quarter 2008 consolidated sales revenues
Earnings Release Classification · 98% confidence The document explicitly states it is a "press release" detailing "Consolidated sales revenues" for the "Third quarter 2008" and the "First 9 months in 2008". This content structure—providing key financial highlights (revenues, cash position, outlook) for a specific reporting period (quarterly/interim) immediately following the period's close—is the definition of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of the results. Q3 2008
2008-11-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.